Spark prices its gene therapy as most expensive U.S. medicine — but with plans to ease cost concerns
The first gene therapy in the U.S. to treat a rare, inherited disease — made by $ONCE — now has a price tag.
The first gene therapy in the U.S., approved last month to treat a rare, inherited form of blindness, now has a price tag: $850,000.
That makes the treatment, called Luxturna and made by Spark Therapeutics, the most expensive medicine sold in the U.S., ranked by sticker price.
But Spark CEO Jeff Marrazzo says Luxturna’s ability to restore vision in a small number of people with a defective gene or more for Luxturna, so the actual price will be considered a bargain by some.
